The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction.
The usual treatments for DGp include nutritional assessment and dietary modifications, glycemic control, prokinetic agents, and anti-emetic agents.Patients with DGp often present with gastric comorbidities, including gastroesophageal reflux disease, intestinal dysmotility and fungal and bacterial infections of the GI tract, as well as, with macro- and micro-vascular complications of diabetes. Therefore, effective management of patients with DGP often requires an interdisciplinary approach with the involvement of a team of specialists
Request for Sample Pages:
DelveInsight’s ‘Diabetic Gastroparesis Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Diabetic Gastroparesis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The DelveInsight Diabetic Gastroparesis epidemiology report gives a thorough understanding of the Diabetic Gastroparesis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Diabetic Gastroparesis in the US, Europe, and Japan. The report covers the detailed information of the Diabetic Gastroparesis epidemiology scenario in seven major countries (US, EU5, and Japan).
Key Highlights Of The Report
Among the 7MM, the US is expected to account for the 62% USD of the overall market size of Diabetic Gastroparesis in 2030
About 40% of patients with Type 1 Diabetes have gastroparesis as per studies carried out in tertiary care centres while approximately ~30% of Type 2 DM cases suffer from DGp.
The total prevalent population of Diabetic Gastroparesis in the 7MM is expected to rise to 17,859,995 in 2030, during the study period [2017–2030]. Estimates show the highest prevalent population of Diabetic Gastroparesis is in the United States followed by the United Kingdom.
Market Size of Diabetic Gastroparesis in the 7MM is expected to reach USD 4331.47 million by 2030
Among the EU-5 countries, Germany accounts for the highest market size for Diabetic Gastroparesis followed by the United Kingdom, Spain, Italy, Germany and France
The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes in which the stomach takes too long to empty its contents (delayed gastric emptying).
Delveinsight’s Diabetic Gastroparesis epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries.
The Diabetic Gastroparesis epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM.
The Diabetic Gastroparesis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030.
It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Scope of the Report
The report provides insight into the historical and forecasted patient pool of Diabetic Gastroparesis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of Diabetic Gastroparesis.
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
The Diabetic Gastroparesis report provides a detailed overview explaining Diabetic Gastroparesis causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
The Diabetic Gastroparesis Epidemiology Report and Model provide an overview of the risk factors and global trends of Diabetic Gastroparesis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).
The report provides the segmentation of the Diabetic Gastroparesis epidemiology.
Key Benefit of Diabetic Gastroparesis Epidemiology Report
The Diabetic Gastroparesis Epidemiology report will allow the user to –
Develop business strategies by understanding the trends shaping and driving the global Diabetic Gastroparesis market
Quantify patient populations in the global Diabetic Gastroparesis market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Diabetic Gastroparesis therapeutics in each of the markets covered
Understand the magnitude of Diabetic Gastroparesis population by its epidemiology
The Diabetic Gastroparesis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Table of Contents
Executive Summary of Diabetic Gastroparesis
Diabetic Gastroparesis Disease Background and Overview
Diabetic Gastroparesis Patient Journey
Diabetic Gastroparesis Epidemiology and Patient Population
Diabetic Gastroparesis Treatment Algorithm, Current Treatment, and Medical Practices
KOL Views on Diabetic Gastroparesis
Diabetic Gastroparesis Unmet Needs
*The table of contents is not exhaustive; will be provided in the final report
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
DelveInsight’s ‘Diabetic Gastroparesis (DGp) – Market Insights, Epidemiology and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DGp in the 7 Major Markets (MM) ,i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Diabetic Gastroparesis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Gastroparesis market.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States